Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland. She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors.
@TiburioT
#neuroendocrine #pituitaryadenoma #chiefmedicalofficer #raredisease #NFPA
Tiburio Therapeutics
Download the PDF file of the interview here.
Empowered Patient Podcast